NCT05783791 is a clinical trial of Newborn Screening Assay in Angelman Syndrome, sponsored by University of Wisconsin, Madison.

Who is sponsoring NCT05783791?

NCT05783791 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT05783791?

Interventions in NCT05783791: Newborn Screening Assay.

What condition does NCT05783791 study?

NCT05783791 studies Angelman Syndrome, Prader-Willi Syndrome.

Is NCT05783791 still recruiting?

NCT05783791 is currently completed. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT05783791

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

Completed Last updated 6 September 2023

What this trial tests

trial testing Newborn Screening Assay in Angelman Syndrome in 11 participants. Completed in 21 July 2023.

Timeline

20 April 2023

Primary endpoint
21 July 2023

21 July 2023

Quick facts

Lead sponsor	University of Wisconsin, Madison
Status	Completed
Study type	OBSERVATIONAL
Enrollment	11
Start date	20 April 2023
Primary completion	21 July 2023
Estimated completion	21 July 2023
Sites	1 location across United States

Drugs / interventions tested

Newborn Screening Assay

Conditions studied

Angelman Syndrome — all drugs for Angelman Syndrome →
Prader-Willi Syndrome — all drugs for Prader-Willi Syndrome →

Sponsor

University of Wisconsin, Madison

Who can join

Eligibility, any sex, with Angelman Syndrome or Prader-Willi Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall purpose of this project is to establish the capability of screening for Angelman syndrome (AS) and Prader-Willi syndrome (PWS) in public health newborn screening (NBS) programs, with an aim of developing and validating a screening test for AS and PWS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Angelman Syndrome

Currently open trials in the same condition.

NCT07181837 — A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome · Phase 1, PHASE2 · recruiting
NCT06353620 — Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy · recruiting
NCT06115109 — Angelman Natural History Study - FAST Spain · recruiting
NCT05293184 — The Global Angelman Syndrome Registry · recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05783791 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05783791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing